Does Louisiana Medicaid cover Zepbound?

Quick answer · Osa

Louisiana Medicaid covers Zepbound for osa with prior authorization on Medicaid.

The card and program names below are mapped to Louisiana Medicaid in our records. Coverage depends on the reason for treatment and the requirements in the policy.

Policy last verified June 2, 2026. Policy effective January 1, 2026. Source: Zepbound.06052025.pdf. How we verify this data.

Card and program names on file in Louisiana

Select a name to read the Louisiana Medicaid policy for Zepbound. These are names we recognize, including older names and spelling variants; this is not a list of plans currently accepting members.

Don't see your card name? Check your card or call the pharmacy-benefit number on your card. If you also have Medicare, confirm which plan handles this prescription.

Zepbound for Osa

Medicaid

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • 6 months of a documented diet and exercise program
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Approval — OSA with PAP therapy

All of:

  • Recipient is 18 years of age or older
  • Established diagnosis of moderate to severe OSA with AHI >= 15 on polysomnography (PSG) within the previous 12 months
  • Recipient does not have central or mixed sleep apnea
  • Recipient does not have type 1 or type 2 diabetes
  • BMI >= 30 kg/m2
  • Prescriber attests medication will not be used concurrently with other tirzepatide products or GLP-1 receptor agonists
  • Tirzepatide used as adjunct to standard of care (individualized healthy lifestyle counseling AND behavioral modification including reduced calorie diet and increased physical activity)

Plus any one of:

  • Medication is prescribed concurrently with PAP therapy, unless PAP is contraindicated or causes clinically significant adverse effects
  • Recipient has a history of non-adherence to PAP therapy

Continuation Approval — Weight loss >= 5%

All of:

  • Recipient is currently receiving medication as evidenced by paid pharmacy claims
  • Documentation confirms recipient met initial approval criteria and has received medication for at least 28 days
  • At least 3 months follow-up documentation showing decreased AHI and improved OSA symptoms
  • Tirzepatide used as adjunct to standard of care (individualized healthy lifestyle counseling AND behavioral modification)
  • Request is for maintenance dose of 10mg or 15mg once weekly (if appropriate per titration schedule)

Plus any one of:

  • Recipient lost >= 5% of baseline body weight OR maintained initial 5% weight loss with no additional weight gain

Continuation Approval — Weight loss < 5% with clinical justification (first occurrence)

All of:

  • Recipient is currently receiving medication as evidenced by paid pharmacy claims
  • Documentation confirms recipient met initial approval criteria and has received medication for at least 28 days
  • Recipient did NOT reach weight loss goal of at least 5% AND clinical justification for continuation is provided
  • At least 3 months follow-up documentation showing decreased AHI and improved OSA symptoms
  • Tirzepatide used as adjunct to standard of care (individualized healthy lifestyle counseling AND behavioral modification)
  • Request is for maintenance dose of 10mg or 15mg once weekly (if appropriate per titration schedule)
  • Previous continuation approval was NOT for a 3-month duration (i.e., this is not a repeat <5% weight loss approval)

Documentation to bring

  • Completed Louisiana Uniform Prescription Drug Prior Authorization Form
  • Completed Tirzepatide (Zepbound) Treatment Agreement for Louisiana Medicaid Recipients (for initiation requests)
  • Polysomnography (PSG) test results showing AHI >= 15, with date of test within the previous 12 months
  • Documentation of most recent BMI calculation (date and result), confirming BMI >= 30 kg/m2
  • Prescriber attestation that recipient does not have central or mixed sleep apnea
  • Prescriber attestation that recipient does not have type 1 or type 2 diabetes
  • Prescriber attestation regarding PAP therapy status: concurrent PAP use (unless contraindicated or causing adverse effects) OR history of non-adherence to PAP therapy
  • Prescriber attestation that tirzepatide will not be used with other tirzepatide products or GLP-1 receptor agonists
  • Prescriber attestation that tirzepatide will be used as adjunct to standard of care (lifestyle counseling and behavioral modification)
  • For continuation: Evidence of current medication use via paid pharmacy claims
  • For continuation: Documentation that recipient met initial approval criteria and has been on therapy at least 28 days
  • For continuation: Baseline body weight prior to initiation of therapy and current body weight with dates
  • For continuation: At least 3 months of follow-up documentation (clinical visit notes or updated test results) showing decreased AHI and OSA symptom improvement
  • For continuation: Clinical justification if weight loss goal of >= 5% was not achieved

Approval and renewal

  • Initial approval: 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Recipient must demonstrate: (1) weight loss >= 5% of baseline body weight OR maintenance of initial 5% weight loss with no additional weight gain — or if <5% weight loss, clinical justification must be provided; AND (2) at least 3 months follow-up documentation (clinic notes or updated test results) showing decreased AHI and improved OSA symptoms. Continuation approval duration: 12 months if weight loss >5%; 3 months if weight loss <5% with clinical justification (if previously approved for 3 months with <5% weight loss, do not approve again). Diabetes exclusion and BMI requirement are not re-verified at continuation; however, lifestyle program adherence is re-affirmed. Maintenance dose of 10mg or 15mg once weekly is required for continuation (if appropriate per titration schedule), at least 4 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 10 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes (both T1DM and T2DM are excluded for this indication)
  • Central or mixed sleep apnea
  • Concurrent use with other tirzepatide products
  • Concurrent use with any GLP-1 receptor agonists
  • Type 1 diabetes

Policy note: This is a Louisiana Medicaid policy effective January 2026 (policy created June 2025). The OSA must be moderate to severe (AHI >= 15). PAP therapy is required concurrently unless contraindicated, clinically adverse, or if recipient has a documented history of PAP non-adherence — these are presented as two alternative qualifying conditions, not a strict step-therapy requirement. The policy explicitly excludes both T1DM and T2DM patients from this indication. Continuation approval duration is variable: 12 months for >= 5% weight loss; 3 months for < 5% with clinical justification; no approval if previously approved for 3 months and < 5% weight loss is again the result. Maintenance dose of 10mg or 15mg required at continuation.

Policy effective January 1, 2026 · verified June 2, 2026 · source: Zepbound.06052025.pdf

Full Louisiana Medicaid coverage page for Zepbound

Other medications under Louisiana Medicaid

All insurance plans · All medications

This page summarizes written Medicaid policies on file. It is not a guarantee of coverage or medical advice. Confirm your current benefits and prior-authorization requirements with your plan.